Overview

A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis Catheters

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This was a Phase III, randomized, double-blind, placebo-controlled study conducted at 37 centers in the United States. 150 subjects ≥ 16 years of age who required hemodialysis (HD) and had a dysfunctional HD catheter were enrolled in the study.
Phase:
Phase 3
Details
Lead Sponsor:
Genentech, Inc.
Treatments:
Tenecteplase
Tissue Plasminogen Activator